Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Neurocrine Biosciences NBIX Stock Holding History

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-53,954	Closed	-$6.78M	–	56
2025 Q2	$6.78M	Hold	53,954	–	–	0.8%	27
2025 Q1	$5.97M	Hold	53,954	–	–	1.23%	24
2024 Q4	$7.36M	Sell	53,954 -193,089	-78%	-$23.9M	0.89%	35
2024 Q3	$28.5M	Buy	247,043 +187,618	+316%	+$25.7M	3.95%	7
2024 Q2	$8.18M	Hold	59,425	–	–	1.33%	26
2024 Q1	$8.2M	Hold	59,425	–	–	1.26%	25
2023 Q4	$7.83M	Hold	59,425	–	–	1.78%	20
2023 Q3	$6.69M	Hold	59,425	–	–	2.11%	17
2023 Q2	$5.6M	Hold	59,425	–	–	1.63%	21
2023 Q1	$6.01M	Hold	59,425	–	–	2.13%	20
2022 Q4	$7.1M	Hold	59,425	–	–	3.08%	17
2022 Q3	$6.31M	Buy	+59,425	New	+$6.03M	2.98%	18

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's NBIX Position: Q3 2025 in Review

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 53,954 shares — an estimated $6.78M sold.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in NBIX in Q3 2022 and held it in 12 quarters. The position peaked at $28.5M in Q3 2024. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne sold 53,954 Neurocrine Biosciences shares in Q3 2025, an estimated $6.78M.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne first reported a position in Neurocrine Biosciences in Q3 2022 and held it in 12 quarters.
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's Neurocrine Biosciences position peaked at $28.5M in Q3 2024.
650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Nationale-Nederlanden Powszechne Towarzystwo Emerytalne's 13F filing for Q3 2025, filed 12 Nov 2025.